Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn’s Disease: A Multicentre Study

Effectiveness of Ustekinumab Dose Escalation in Patients with Crohn’s Disease

(2020) Jacob E. Ollech et al.   Clinical Gastroenterology and Hepatology

Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

(2019) Bram Verstockt et al.   Journal of Crohns & Colitis

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

(2019) Vince B C Biemans et al.   Journal of Crohns & Colitis

Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response

(2019) Miles P Sparrow et al.   Journal of Crohns & Colitis

How, When, and For Whom Should We Perform Therapeutic Drug Monitoring?

(2019) Severine Vermeire et al.   Clinical Gastroenterology and Hepatology

Two Cases of Inflammatory Bowel Disease Patients Treated With Ustekinumab 90 mg Every 3 Weeks

(2019) Thomas Chateau et al.   INFLAMMATORY BOWEL DISEASES

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

(2019) Joana Torres et al.   Journal of Crohns & Colitis

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

(2018) P. Wils et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

(2018) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

(2017) Joseph D. Feuerstein et al.   GASTROENTEROLOGY

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohnʼs Disease

(2017) Christopher Ma et al.   INFLAMMATORY BOWEL DISEASES

Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge

(2016) Julia Salleron et al.   Journal of Crohns & Colitis

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases

(2014) Xavier Roblin et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY